Influenza vaccination coverage one year after the A(H1N1) influenza pandemic, France, 2010–2011

Guthmann, Jean-Paul; Fonteneau, Laure; Bonmarin, Isabelle; Lévy-Brühl, Daniel

doi:10.1016/j.vaccine.2011.12.011

Cited by 34 publications

(43 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] The voucher allows the recipients to get the vaccine from the pharmacist. In recent years, thanks to this system, target population vaccination coverage (VC) has been annually estimated by the National Health Insurance Scheme for Employees (Caisse Nationale d'Assurance Maladie des Travailleurs Salariés-CNAMTS), the main social security scheme, covering about 85% of the French population.…”

Section: Introductionmentioning

confidence: 99%

“…In recent years, thanks to this system, target population vaccination coverage (VC) has been annually estimated by the National Health Insurance Scheme for Employees (Caisse Nationale d'Assurance Maladie des Travailleurs Salariés-CNAMTS), the main social security scheme, covering about 85% of the French population. [1][2][3] For the 2010/2011 season, the recommended trivalent influenza vaccine included the influenza pandemic strain A/ California/07/2009, in addition to the H3N2 A/Perth/16/2009 and B/Brisbane/68/2008 strains. 4 The French 2010/2011 influenza vaccination campaign lasted from September 2010 to January 2011 with 12 million of people receiving influenza vaccine vouchers.…”

Section: Introductionmentioning

confidence: 99%

“…4 The French 2010/2011 influenza vaccination campaign lasted from September 2010 to January 2011 with 12 million of people receiving influenza vaccine vouchers. 1,2 The influenza vaccination strategy targets three main at risk groups: persons aged 65 year old (y.o.) or above, health professionals and persons below 65 y.o.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Field seasonal influenza vaccine effectiveness

Falchi

Souty

Grisoni

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Field seasonal influenza vaccine effectiveness

Falchi

Souty

Grisoni

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…As in the general population: Diphtheria -Tetanus -Poliomyelitis -Pertussis Meningococcal C (for patients < 24 years) Human Papillomavirus (HPV) (in girls aged [11][12][13][14][15][16][17][18][19] Meningococcal C (previously unvaccinated MSM aged over 24). BCG is contraindicated regardless of immune status in HIVinfected adults.…”

Section: General Principlesmentioning

confidence: 99%

“…11 Seasonal flu vaccine coverage was estimated to be 30.9% in a French hospital-based cohort analyzed in 2011, 7 compared to 37.5 to 48.5% in global high risk populations. 12 In the USA, in a prospective observational cohort study of 9131 HIV-infected patients analysed during 8 influenza seasons (1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008), the mean percentage of patients annually vaccinated against influenza was only 35%. 13 In France, pneumococcal vaccine coverage has increased in HIV-infected people since the 2009 A/H1N1 influenza pandemic: it reached nearly 65% in a patient cohort study conducted in 2011, whereas it was only 3.3% in several French studies conducted before the pandemic.…”

Section: Vaccine Coveragementioning

confidence: 99%

Immunization of HIV-infected adult patients — French recommendations

Frésard

Gagneux‐Brunon

Lucht

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-infected patients remain at increased risk of infection including vaccine-preventable diseases. Vaccines are therefore critical components in the protection of HIV-infected patients from an increasing number of preventable diseases. However, missed opportunities for vaccination among HIV-infected patients persist and vaccine coverage in this population could be improved. This article presents the French recommendations regarding immunization of HIV-infected adults in the light of the evidence-based literature on the benefits and the potential risks of vaccines among this vulnerable population.

show abstract

Mapping trends and hotspots in research on global influenza vaccine hesitancy: A bibliometric analysis

Zhang,

Tang,

Huang

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsInfluenza is one of the most widespread respiratory infections and poses a huge burden on health care worldwide. Vaccination is key to preventing and controlling influenza. Influenza vaccine hesitancy is an important reason for the low vaccination rate. In 2019, Vaccine hesitancy was identified as one of the top 10 threats to global health by the World Health Organization. However, there remains a glaring scarcity of bibliometric research in that regard. This study sought to identify research hotspots and future development trends on influenza vaccine hesitation and provide a new perspective and reference for future research.MethodsWe retrieved publications on global influenza vaccine hesitancy from the Web of Science Core Collection database, Scopus, and PubMed databases from inception to 2022. This study used VOSviewer and CiteSpace for visualization analysis.ResultsInfluenza vaccine hesitancy‐related publications increased rapidly from 2012 and peaked in 2022. One hundred and nine countries contributed to influenza vaccine hesitation research, and the United States ranked first with 541 articles and 7161 citations. Vaccines‐Basel was the journal with the largest number of published studies on influenza vaccine hesitations. MacDonald was the most frequently cited author. The most popular research topics on influenza vaccine hesitancy were (1) determinants of influenza vaccination in specific populations, such as healthcare workers, children, pregnant women, and so on; (2) influenza and COVID‐19 vaccine hesitancy during the COVID‐19 pandemic.ConclusionsThe trend in the number of annual publications related to influenza vaccine hesitancy indicating the COVID‐19 pandemic will prompt researchers to increase their attention to influenza vaccine hesitancy. With healthcare workers as the key, reducing vaccine hesitancy and improving vaccine acceptance in high‐risk groups will be the research direction in the next few years.

show abstract

Influenza vaccination coverage one year after the A(H1N1) influenza pandemic, France, 2010–2011

Cited by 34 publications

References 5 publications

Field seasonal influenza vaccine effectiveness

Field seasonal influenza vaccine effectiveness

Immunization of HIV-infected adult patients — French recommendations

Mapping trends and hotspots in research on global influenza vaccine hesitancy: A bibliometric analysis

Contact Info

Product

Resources

About